DOCSLIB.ORG

Ketoconazole Binds to Glucocorticoid Receptors and Exhibits Glucocorticoid Antagonist Activity in Cultured Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ketoconazole Binds to Glucocorticoid Receptors and Exhibits Glucocorticoid Antagonist Activity in Cultured Cells Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. D S Loose, … , E P Stover, D Feldman J Clin Invest. 1983;72(1):404-408. https://doi.org/10.1172/JCI110982. Research Article We have recently found that ketoconazole inhibits adrenal steroidogenesis; in this paper we investigated whether imidazole antimycotic drugs additionally interact with glucocorticoid receptor sites in target tissues. Our approach was to assess the ability of three drugs: ketoconazole, clotrimazole, and RS 49910, to inhibit [3H]dexamethasone binding to hepatoma tissue culture (HTC) cell cytosol. The results indicated dose-dependent, competitive displacement of [3H]dexamethasone binding that was in the potency sequence: clotrimazole greater than ketoconazole greater than RS 49910. We then examined the functional response of this binding by measuring tyrosine aminotransferase (TAT) activity in HTC cells. The antimycotics did not exhibit TAT agonist activity and inhibition of basal enzyme levels was not detected. However, the drugs were potent antagonists of dexamethasone-induced TAT activity and the effect was temporally reversible. This antagonist activity was in the same sequence and closely correlated with the binding potency of the three drugs. We conclude that ketoconazole and other imidazole antimycotic drugs possess glucocorticoid antagonist activity by virtue of occupancy of glucocorticoid receptor sites in target tissues. Find the latest version: https://jci.me/110982/pdf Ketoconazole Binds to Glucocorticoid Receptors and Exhibits Glucocorticoid Antagonist Activity in Cultured Cells DAVID S. LOOSE, E. PRICE STOVER, and DAVID FELDMAN, Stanford University School of Medicine, Department of Medicine, Stanford, California 94305 A B S T R A C T We have recently found that ketocon- onstrated that ketoconazole is a potent inhibitor of ste- azole inhibits adrenal steroidogenesis; in this paper we roidogenesis both in volunteers and in in vitro studies investigated whether imidazole antimycotic drugs ad- with adrenal (2, 3) and testicular cells (4). Because ditionally interact with glucocorticoid receptor sites other drugs known to inhibit steroidogenesis (5) also in target tissues. Our approach was to assess the ability compete for specific steroid receptor binding sites in of three drugs: ketoconazole, clotrimazole, and RS target tissues (6), we proceeded to examine the pos- 49910, to inhibit [3H]dexamethasone binding to hep- sibility that ketoconazole might additionally interact atoma tissue culture (HTC) cell cytosol. The results with glucocorticoid receptors. Since numerous other indicated dose-dependent, competitive displacement imidazole antimycotic drugs are available or are in of [3H]dexamethasone binding that was in the potency various stages of development (1), we also examined sequence: clotrimazole > ketoconazole > RS 49910. two additional structurally related drugs to ascertain We then examined the functional response of this whether any activity found for ketoconazole was spe- binding by measuring tyrosine aminotransferase (TAT) cific to that molecule or represented more general activity in HTC cells. The antimycotics did not exhibit properties associated with the imidazole antifungal TAT agonist activity and inhibition of basal enzyme drugs as a family. Two sets of experiments were un- levels was not detected. However, the drugs were po- dertaken. First, the antifungal agents were tested for tent antagonists of dexamethasone-induced TAT ac- their ability to compete with [3H]dexamethasone for tivity and the effect was temporally reversible. This glucocorticoid receptor binding sites in cytosol pre- antagonist activity was in the same sequence and pared from hepatoma tissue culture (HTC)' cells, a closely correlated with the binding potency of the classical glucocorticoid target system (7, 8). Second, three drugs. We conclude that ketoconazole and other the antifungal drugs were tested in HTC cells for their imidazole antimycotic drugs possess glucocorticoid ability to either induce or inhibit the glucocorticoid antagonist activity by virtue of occupancy of gluco- induction of the enzyme tyrosine aminotransferase corticoid receptor sites in target tissues. (TAT; 7, 8). The results of these studies indicate that ketoconazole, and the other related antifungal agerits, INTRODUCTION competitively inhibit [3H]dexamethasone binding to HTC cell glucocorticoid receptors and effectively Ketoconazole is an important new antifungal agent block dexamethasone induction of TAT. These find- because of its effectiveness against a wide variety of ings raise the possibility that this class of drugs may pathogenic fungi after oral administration and its lim- prove useful as glucocorticoid antagonists. ited number of side effects (1). However, recent in- vestigations in this and other laboratories have dem- METHODS Cells and tissue culture. HTC cells were routinely grown in T75 flasks in Dulbecco's Modified Eagle's Medium sup- Address all correspondence to Dr. Feldman. Received for publication 22 February 1983 and in revised ' Abbreviations used in this paper: HTC, hepatoma tissue form 6 April 1983. culture; TAT, tyrosine aminotransferase. 404 J. Clin. Invest. © The American Society for Clinical Investigation, Inc. * 0021-9738/83/07/0404/05 $1.00 Volume 72 July 1983 404-408 plemented with 5% newborn calf serum, 5% fetal calf serum (all from Gibco, Grand Island, NY), and 1 g/liter glucose. For binding studies, cells were grown for 7-8 d (confluence) with a medium change on days 2 and 5. For enzyme assays, o 4910 cells were grown for 4-5 d, with serum-free medium used for the last 24 h. oz 75 KETO Binding assays. Cytosol binding studies were performed using previously reported techniques (9). Briefly, cells were z at 0°C in a uw50-- harvested by scraping and lysed by sonication z medium containing 250 mM sucrose, 1.5 mM EDTA, 10 mM 0 Tris, 12 mM monothioglycerol, and 10 mM sodium molyb- ,, CLO < a date, pH 7.8. Cytosol was prepared by centrifugation at O 204,000 g for 30 min. Glucocorticoid receptors were assayed ui 25 by incubating aliquots of cytosol with [3H]dexamethasone x (26 Ci/mmol, Amersham Corp., Arlington Heights, IL) with 0 -v- .. or without competitors for 3 h at 0°C. A correction for non- 1 10 100 specific binding was made in all experiments by subtracting that binding resistant to a 250-fold molar excess of radioinert ANTIMYCOTIC DRUG CONCENTRATION (PM) dexamethasone. Bound hormone was separated from free FIGURE 1 Antifungal drug competition for specific hormone using mini-columns made with G-50 fine Sephadex [3H]dexamethasone binding sites in HTC cell cytosol. Cytosol (Pharmacia Fine Chemicals, Piscataway, NJ; 9). was incubated with 13 nM [3H]dexamethasone with or with- Tyrosine aminotransferase activity. TAT activity was out the indicated concentration of competitors for 3 h at assessed by a spectrophotometric method (7, 8). Cells were 0°C. Results are expressed as a percentage of control binding treated with various antifungal agents with or without dexa- obtained in the absence of competitors (109±14 fmol/mg methasone for 20 h, lysed by sonication, and aliquots of the protein). Values shown are mean±SE of four to six deter- 8,000-g supernatant were assayed. Soluble protein was de- minations. CLO, clotrimazole; KETO, ketoconazole, 49910, termined by the method of Bradford (10). Syntex drug RS 49910. Drugs. Ketoconazole was obtained from Janssen (Beerse, Belgium). Clotrimazole (11), a topical antifungal developed by Bayer, and RS 49910, an aryloxy-substituted alkylim- against [3H]estradiol binding to estrogen receptors in idazole (Syntex experimental antifungal), were both ob- tained from Syntex (Palo Alto, CA). Since circulating drug rat uterus (13) and against [3H]1,25(OH)2vitamin D3 levels are usually expressed on the basis of microgram per binding to vitamin D receptors in rat intestine (14). milliliter and all of our studies are based on molar concen- In both cases, 10 gg/ml of ketoconazole failed to sig- trations, we note here that 1.88 gM ketoconazole is equiv- nificantly compete for the binding sites indicating that alent to 1 Ag/ml. the action against the glucocorticoid receptor was re- ceptor-specific. Second, Lineweaver-Burk analysis of the ketoconazole competition for the glucocorticoid RESULTS receptor revealed that the inhibition of binding was Ability of antimycotics to compete for receptor competitive in nature. Third, these inhibitors were also binding sites. Our first experiments were designed examined against glucocorticoid receptors freshly pre- to ascertain whether antifungal drugs competed with pared from either kidney or thymus cytosol obtained [3H]dexamethasone for glucocorticoid receptor bind- from adrenalectomized rats (9). The results were es- ing sites. As shown in Fig. 1, each of the three drugs sentially the same as with HTC cell cytosol. inhibited [3H]dexamethasone binding to HTC cell cy- Effect of antimycotic drugs on TA T induction. tosol, but with a widely differing spectrum of activity. Occupancy of the glucocorticoid receptor may result The order of potency and the concentration inhibiting in either the expression of a glucocorticoid-induced 50% [3H]dexamethasone binding was: clotrimazole (0.7 function (agonist activity) or blockade of a function AM or 0.24 jug/ml) > ketoconazole (20 MM or 10 ,g/ induced by glucocorticoids (antagonist activity). To ml) > RS-49910 (50 MM or 21 Ag/ml). To put these determine which of these possibilities resulted from
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Prednisolone Versus Dexamethasone for Croup: a Randomized Controlled Trial Colin M
    Prednisolone Versus Dexamethasone for Croup: a Randomized Controlled Trial Colin M. Parker, MBChB, DCH, MRCPCH, FACEM,a,b Matthew N. Cooper, BCA, BSc, PhDc OBJECTIVES: The use of either prednisolone or low-dose dexamethasone in the treatment of abstract childhood croup lacks a rigorous evidence base despite widespread use. In this study, we compare dexamethasone at 0.6 mg/kg with both low-dose dexamethasone at 0.15 mg/kg and prednisolone at 1 mg/kg. METHODS: Prospective, double-blind, noninferiority randomized controlled trial based in 1 tertiary pediatric emergency department and 1 urban district emergency department in Perth, Western Australia. Inclusions were age .6 months, maximum weight 20 kg, contactable by telephone, and English-speaking caregivers. Exclusion criteria were known prednisolone or dexamethasone allergy, immunosuppressive disease or treatment, steroid therapy or enrollment in the study within the previous 14 days, and a high clinical suspicion of an alternative diagnosis. A total of 1252 participants were enrolled and randomly assigned to receive dexamethasone (0.6 mg/kg; n = 410), low-dose dexamethasone (0.15 mg/kg; n = 410), or prednisolone (1 mg/kg; n = 411). Primary outcome measures included Westley Croup Score 1-hour after treatment and unscheduled medical re-attendance during the 7 days after treatment. RESULTS: Mean Westley Croup Score at baseline was 1.4 for dexamethasone, 1.5 for low-dose dexamethasone, and 1.5 for prednisolone. Adjusted difference in scores at 1 hour, compared with dexamethasone, was 0.03 (95% confidence interval 20.09 to 0.15) for low-dose dexamethasone and 0.05 (95% confidence interval 20.07 to 0.17) for prednisolone.
    [Show full text]
  • Mifepristone
    1. NAME OF THE MEDICINAL PRODUCT Mifegyne 200 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 200-mg mifepristone. For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Tablet. Light yellow, cylindrical, bi-convex tablets, with a diameter of 11 mm with “167 B” engraved on one side. 4. CLINICAL PARTICULARS For termination of pregnancy, the anti-progesterone mifepristone and the prostaglandin analogue can only be prescribed and administered in accordance with New Zealand’s abortion laws and regulations. 4.1 Therapeutic indications 1- Medical termination of developing intra-uterine pregnancy. In sequential use with a prostaglandin analogue, up to 63 days of amenorrhea (see section 4.2). 2- Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester. 3- Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reasons (beyond the first trimester). 4- Labour induction in fetal death in utero. In patients where prostaglandin or oxytocin cannot be used. 4.2 Dose and Method of Administration Dose 1- Medical termination of developing intra-uterine pregnancy The method of administration will be as follows: • Up to 49 days of amenorrhea: 1 Mifepristone is taken as a single 600 mg (i.e. 3 tablets of 200 mg each) oral dose, followed 36 to 48 hours later, by the administration of the prostaglandin analogue: misoprostol 400 µg orally or per vaginum. • Between 50-63 days of amenorrhea Mifepristone is taken as a single 600 mg (i.e. 3 tablets of 200 mg each) oral dose, followed 36 to 48 hours later, by the administration of misoprostol.
    [Show full text]
  • Opposing Effects of Dehydroepiandrosterone And
    European Journal of Endocrinology (2000) 143 687±695 ISSN 0804-4643 EXPERIMENTAL STUDY Opposing effects of dehydroepiandrosterone and dexamethasone on the generation of monocyte-derived dendritic cells M O Canning, K Grotenhuis, H J de Wit and H A Drexhage Department of Immunology, Erasmus University Rotterdam, The Netherlands (Correspondence should be addressed to H A Drexhage, Lab Ee 838, Department of Immunology, Erasmus University, PO Box 1738, 3000 DR Rotterdam, The Netherlands; Email: [email protected]) Abstract Background: Dehydroepiandrosterone (DHEA) has been suggested as an immunostimulating steroid hormone, of which the effects on the development of dendritic cells (DC) are unknown. The effects of DHEA often oppose those of the other adrenal glucocorticoid, cortisol. Glucocorticoids (GC) are known to suppress the immune response at different levels and have recently been shown to modulate the development of DC, thereby influencing the initiation of the immune response. Variations in the duration of exposure to, and doses of, GC (particularly dexamethasone (DEX)) however, have resulted in conflicting effects on DC development. Aim: In this study, we describe the effects of a continuous high level of exposure to the adrenal steroid DHEA (1026 M) on the generation of immature DC from monocytes, as well as the effects of the opposing steroid DEX on this development. Results: The continuous presence of DHEA (1026 M) in GM-CSF/IL-4-induced monocyte-derived DC cultures resulted in immature DC with a morphology and functional capabilities similar to those of typical immature DC (T cell stimulation, IL-12/IL-10 production), but with a slightly altered phenotype of increased CD80 and decreased CD43 expression (markers of maturity).
    [Show full text]
  • Canine Vascular Tissues Are Targets for Androgens, Estrogens, Progestins, and Glucocorticoids
    Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. K B Horwitz, L D Horwitz J Clin Invest. 1982;69(4):750-758. https://doi.org/10.1172/JCI110513. Research Article Sex differences and steroid hormones are known to influence the vascular system as shown by the different incidence of atherosclerosis in men and premenopausal women, or by the increased risk of cardiovascular diseases in women taking birth control pills or men taking estrogens. However, the mechanisms for these effects in vascular tissues are not known. Since steroid actions in target tissues are mediated by receptors, we have looked for cytoplasmic steroid receptor proteins in vascular tissues of dogs. We find specific saturable receptors, sedimenting at 8S on sucrose density gradients for estrogens (measured with [3H]estradiol +/- unlabeled diethylstilbestrol), androgens (measured with [3H]R1881 +/- unlabeled R1881 and triamcinolone acetonide), and glucocorticoids (measured with [3H]dexamethasone +/- unlabeled dexamethasone); they are absent for progesterone (measured with [3H]R5020 +/- unlabeled R5020 and dihydrotestosterone). Progesterone receptors can, however, be induced by 1-wk treatment of dogs with physiological estradiol concentrations (100 pg/ml serum estrogen), indicating a functional estrogen receptor. Receptor levels range from 20 to 2,000 fmol/mg DNA. They are specific for each hormone; unrelated steroids fail to complete for binding. Low dissociation constants, measured by Scatchard analyses, show that binding is of high affinity. Steroid binding sites are in the media and/or adventitia since they persist when the intima is removed. Compared with the arteries, receptor levels are reduced 80% in inferior venae cavae of […] Find the latest version: https://jci.me/110513/pdf Canine Vascular Tissues Are Targets for Androgens, Estrogens, Progestins, and Glucocorticoids KATHRYN B.
    [Show full text]
  • Dexamethasone Inhibits the Induction of NAD+-Dependent 15
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1497 (2000) 61^68 www.elsevier.com/locate/bba Dexamethasone inhibits the induction of NAD-dependent 15-hydroxyprostaglandin dehydrogenase by phorbol ester in human promonocytic U937 cells Min Tong 1, Hsin-Hsiung Tai * Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0082, USA Received 29 December 1999; received in revised form 2 March 2000; accepted 9 March 2000 Abstract Pro-inflammatory prostaglandins are known to be first catabolized by NAD-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) to inactive metabolites. This enzyme is under regulatory control by various inflammation-related agents. Regulation of this enzyme was investigated in human promonocytic U937 cells. 15-PGDH activity was found to be optimally induced by phorbol 12-myristate 13-acetate (PMA) at 10 nM after 24 h of treatment. The induction was blocked by staurosporine or GF 109203X indicating that the induction was mediated by protein kinase C. The induction by PMA was inhibited by the concurrent addition of dexamethasone. Nearly complete inhibition was observed at 50 nM. Other glucocorticoids, such as hydrocortisone and corticosterone, but not sex hormones, were also inhibitory. Inhibition by dexamethasone could be reversed by the concurrent addition of antagonist mifepristone (RU-486) indicating that the inhibition was a receptor-mediated event. Either induction by PMA or inhibition by dexamethasone the 15-PGDH activity correlated well with the enzyme protein expression as shown by the Western blot analysis. These results provide the first evidence that prostaglandin catabolism is regulated by glucocorticoids at the therapeutic level.
    [Show full text]
  • Dexamethasone in Patients with Acute Lung Injury from Acute Monocytic Leukaemia
    Eur Respir J 2012; 39: 648–653 DOI: 10.1183/09031936.00057711 CopyrightßERS 2012 Dexamethasone in patients with acute lung injury from acute monocytic leukaemia E´. Azoulay*, E. Canet*, E. Raffoux#, E. Lengline´#, V. Lemiale*, F. Vincent*, A. de Labarthe#, A. Seguin*, N. Boissel#, H. Dombret# and B. Schlemmer* ABSTRACT: The use of steroids is not required in myeloid malignancies and remains AFFILIATIONS controversial in patients with acute lung injury (ALI) or acute respiratory distress syndrome *Medical ICU and #Hematology Dept, Saint-Louis (ARDS). We sought to evaluate dexamethasone in patients with ALI/ARDS caused by acute Hospital, Paris, France. monocytic leukaemia (AML FAB-M5) via either leukostasis or leukaemic infiltration. Dexamethasone (10 mg every 6 h until neutropenia) was added to chemotherapy and intensive CORRESPONDENCE ´ care unit (ICU) management in 20 consecutive patients between 2005 and 2008, whose data were E. Azoulay AP-HP compared with those from 20 historical controls (1994–2002). ICU mortality was the primary Hoˆpital Saint-Louis criterion. We also compared respiratory deterioration rates, need for ventilation and nosocomial Medical ICU infections. 75010 Paris 17 (85%) patients had hyperleukocytosis, 19 (95%) had leukaemic masses, and all 20 had France E-mail: [email protected] severe pancytopenia. All patients presented with respiratory symptoms and pulmonary infiltrates paris.fr prior to AML FAB-M5 diagnosis. Compared with historical controls, dexamethasone-treated patients had a significantly lower ICU mortality rate (20% versus 50%; p50.04) and a trend for less Received: respiratory deterioration (50% versus 80%; p50.07). There were no significant increases in the May 24 2011 Accepted after revision: rates of infections with dexamethasone.
    [Show full text]
  • Topical Corticosteroids and Fungal Keratitis: a Review of the Literature and Case Series
    Journal of Clinical Medicine Review Topical Corticosteroids and Fungal Keratitis: A Review of the Literature and Case Series Karl Anders Knutsson 1,*, Alfonso Iovieno 2,3, Stanislav Matuska 1, Luigi Fontana 2 and Paolo Rama 1 1 Cornea and Ocular Surface Unit, San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] (S.M.); [email protected] (P.R.) 2 Arcispedale Santa Maria Nuova—IRCCS, 42123 Reggio Emilia, Italy; [email protected] (A.I.); [email protected] (L.F.) 3 Department of Ophthalmology, University of British Columbia, Vancouver, BC V6T 1Z, Canada * Correspondence: [email protected] or [email protected]; Tel./Fax: +39-022-6432-648 Abstract: The management of fungal keratitis is complex since signs and symptoms are subtle and ocular inflammation is minimal in the preliminary stages of infection. Initial misdiagnosis of the condition and consequent management of inflammation with corticosteroids is a frequent occurrence. Topical steroid use is considered to be a principal factor for development of fungal keratitis. In this review, we assess the studies that have reported outcomes of fungal keratitis in patients receiving steroids prior to diagnosis. We also assess the possible rebound effect present when steroids are abruptly discontinued and the clinical characteristics of three patients in this particular clinical scenario. Previous reports and the three clinical descriptions presented suggest that in fungal keratitis, discontinuing topical steroids can induce worsening of clinical signs. In these cases, we recommend to slowly taper steroids and continue or commence appropriate antifungal therapy. Citation: Knutsson, K.A.; Iovieno, A.; Keywords: fungal keratitis; topical corticosteroids; topical steroids; rebound effect Matuska, S.; Fontana, L.; Rama, P.
    [Show full text]
  • Antiprotozoal and Antitumor Activity of Natural Polycyclic Endoperoxides: Origin, Structures and Biological Activity
    molecules Review Antiprotozoal and Antitumor Activity of Natural Polycyclic Endoperoxides: Origin, Structures and Biological Activity Valery M. Dembitsky 1,2,*, Ekaterina Ermolenko 2, Nick Savidov 1, Tatyana A. Gloriozova 3 and Vladimir V. Poroikov 3 1 Centre for Applied Research, Innovation and Entrepreneurship, Lethbridge College, 3000 College Drive South, Lethbridge, AB T1K 1L6, Canada; [email protected] 2 A.V. Zhirmunsky National Scientific Center of Marine Biology, 17 Palchevsky Str., 690041 Vladivostok, Russia; [email protected] 3 Institute of Biomedical Chemistry, 10 Pogodinskaya Str., 119121 Moscow, Russia; [email protected] (T.A.G.); [email protected] (V.V.P.) * Correspondence: [email protected]; Tel.: +1-403-320-3202 (ext. 5463); Fax: +1-888-858-8517 Abstract: Polycyclic endoperoxides are rare natural metabolites found and isolated in plants, fungi, and marine invertebrates. The purpose of this review is a comparative analysis of the pharmacological potential of these natural products. According to PASS (Prediction of Activity Spectra for Substances) estimates, they are more likely to exhibit antiprotozoal and antitumor properties. Some of them are now widely used in clinical medicine. All polycyclic endoperoxides presented in this article demonstrate antiprotozoal activity and can be divided into three groups. The third group includes endoperoxides, which show weak antiprotozoal activity with a reliability of up to 70%, and this group includes only 1.1% of metabolites. The second group includes the largest number of endoperoxides, Citation: Dembitsky, V.M.; which are 65% and show average antiprotozoal activity with a confidence level of 70 to 90%. Lastly, Ermolenko, E.; Savidov, N.; the third group includes endoperoxides, which are 33.9% and show strong antiprotozoal activity with Gloriozova, T.A.; Poroikov, V.V.
    [Show full text]
  • Corticosteroids in Terminal Cancer-A Prospective Analysis of Current Practice
    Postgraduate Medical Journal (November 1983) 59, 702-706 Postgrad Med J: first published as 10.1136/pgmj.59.697.702 on 1 November 1983. Downloaded from Corticosteroids in terminal cancer-a prospective analysis of current practice G. W. HANKS* T. TRUEMAN B.Sc., M.B., B.S., M.R.C.P.(U.K.) S.R.N. R. G. TWYCROSS M.A., D.M., F.R.C.P. Sir Michael Sobell House, The Churchill Hospital, Headington, Oxford OX3 7LJ Summary Introduction Over half of a group of 373 inpatients with advanced Corticosteroids have a major role to play in the malignant disease were treated with corticosteroids control of symptoms in patients with advanced for a variety of reasons. They received either pred- malignant disease. They may be employed in a non- nisolone or dexamethasone, or replacement therapy specific way to improve mood and appetite; or they with cortisone acetate. Forty percent of those receiv- may be indicated as specific adjunctive therapy in the ing corticosteroids benefited from them. A higher relief of symptoms related to a large tumour mass or response rate was seen when corticosteroids were to nerve compression. The management of a numberProtected by copyright. prescribed for nerve compression pain, for raised of other symptoms and syndromes may also be intracranial pressure, and when used in conjunction facilitated by treatment with corticosteroids (Table with chemotherapy. No significant difference in 1). efficacy was noted between the 2 drugs. The results, The use of corticosteroids in patients with ad- however, suggest that with a larger sample, dexame- vanced cancer is empirical, as it is in other non- thasone would have been shown to be significantly endocrine indications.
    [Show full text]
  • Dexamethasone and Fludrocortisone Inhibit Hedgehog Signaling In
    This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. Article Cite This: ACS Omega 2018, 3, 12019−12025 http://pubs.acs.org/journal/acsodf Dexamethasone and Fludrocortisone Inhibit Hedgehog Signaling in Embryonic Cells † ‡ † ‡ Kirti Kandhwal Chahal,*, , Milind Parle, and Ruben Abagyan*, † Department of Pharmaceutical Sciences, G. J. University of Science and Technology, Hisar 125001, India ‡ Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92037, United States ABSTRACT: The hedgehog (Hh) pathway plays a central role in the development and repair of our bodies. Therefore, dysregulation of the Hh pathway is responsible for many developmental diseases and cancers. Basal cell carcinoma and medulloblastoma have well- established links to the Hh pathway, as well as many other cancers with Hh-dysregulated subtypes. A smoothened (SMO) receptor plays a central role in regulating the Hh signaling in the cells. However, the complexities of the receptor structural mechanism of action and other pathway members make it difficult to find Hh pathway inhibitors efficient in a wide range. Recent crystal structure of SMO with cholesterol indicates that it may be a natural ligand for SMO activation. Structural similarity of fluorinated corticosterone derivatives to cholesterol motivated us to study the effect of dexamethasone, fludrocortisone, and corticosterone on the Hh pathway activity. We identified an inhibitory effect of these three drugs on the Hh pathway using a functional assay in NIH3T3 glioma response element cells. Studies using BODIPY-cyclopamine and 20(S)-hydroxy cholesterol [20(S)-OHC] as competitors for the transmembrane (TM) and extracellular cysteine-rich domain (CRD) binding sites showed a non-competitive effect and suggested an alternative or allosteric binding site for the three drugs.
    [Show full text]
  • Ketoconazole Revisited: a Preoperative Or Postoperative Treatment in Cushing's Disease
    European Journal of Endocrinology (2008) 158 91–99 ISSN 0804-4643 CLINICAL STUDY Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease F Castinetti, I Morange, P Jaquet, B Conte-Devolx and T Brue Department of Endocrinology, Diabetes, Metabolic Diseases and Nutrition, Hoˆpital de la Timone, Centre Hospitalier Universitaire de Marseille and Faculte´ de Me´decine, Universite´ de la Me´diterrane´e, 264 rue St Pierre, Cedex 5, 13385 Marseille, France (Correspondence should be addressed to T Brue; Email: [email protected]) Abstract Context: Although transsphenoidal surgery remains the first-line treatment in Cushing’s disease (CD), recurrence is observed in about 20% of cases. Adjunctive treatments each have specific drawbacks. Despite its inhibitory effects on steroidogenesis, the antifungal drug ketoconazole was only evaluated in series with few patients and/or short-term follow-up. Objective: Analysis of long-term hormonal effects and tolerance of ketoconazole in CD. Design: A total of 38 patients were retrospectively studied with a mean follow-up of 23 months (6–72). Setting: All patients were treated at the same Department of Endocrinology in Marseille, France. Patients: The 38 patients with CD, of whom 17 had previous transsphenoidal surgery. Intervention: Ketoconazole was begun at 200–400 mg/day and titrated up to 1200 mg/day until biochemical remission. Main outcome measures: Patients were considered controlled if 24-h urinary free cortisol was normalized. Results: Five patients stopped ketoconazole during the first week because of clinical or biological intolerance. On an intention to treat basis, 45% of the patients were controlled as were 51% of those treated long term.
    [Show full text]